---
company: Altimmune, Inc.
ticker: ALT
form: 8-K
filed: 2026-08-12
accession: 0001326190-26-000049
source: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/
---

# Altimmune (ALT) earnings release, August 12, 2026

Altimmune, Inc. (ALT) · Form 8-K, Item 2.02 · Filed 2026-08-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/)

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

​

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

​

GAITHERSBURG, MD – August 12, 2026 – Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial. The team remains focused on advancing our differentiated pemvidutide franchise in both MASH and AUD, each an area of unmet need with substantial future sales potential,” said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. “We are also pleased to announce completion of enrollment in the RESTORE Phase 2 ALD trial. Our momentum positions Altimmune to deliver on our goals of bringing pemvidutide to patients with serious liver diseases and creating value for shareholders.”

​

Key Highlights and Anticipated Milestones

​

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

​

Alcohol Use Disorder (AUD)

​

Alcohol-associated Liver Disease (ALD)

​

Corporate Updates

​

​

​

​

Financial Results for the Three Months Ended June 30, 2026

​

Conference Call Information:

​

Following the conclusion of the call, the webcast will be available for replay on the IR page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

About Pemvidutide

Pemvidutide is an investigational novel peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that has an effect on reducing liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.

​

The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In July 2026, the Company completed enrollment of the RESTORE Phase 2 trial in ALD.

​

​

​

​

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

​

Follow @Altimmune, Inc. on

LinkedIn

Follow @AltimmuneInc on

X

​

​

​

Forward-Looking Statements

Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, clinical trial study design, status, correspondence, results and data, including the ongoing PERFORMA and RESTORE trials, the timing of key milestones for the Company’s clinical programs, future plans or expectations for pemvidutide for the treatment of MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations, including potential regulatory timeline and approval benefits, the Company’s financial position, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, financial results, and the impact of the changes to our leadership and governance structure, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company’s other filings with the SEC, which are available at www.sec.gov.

Investor Contact:

​

Media Contact:

​

​

​

​

## Financial statements

### Income Statement (Three Months Ended — (In thousands, except share and per-share amounts))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues | $— | 5 | $— | 10 |
| Operating expenses: | Research and development | 18,655 | 17,236 | 34,847 | 33,063 |
| Operating expenses: | General and administrative | 7,574 | 5,691 | 15,626 | 11,684 |
| Operating expenses: | Total operating expenses | 26,229 | 22,927 | 50,473 | 44,747 |
| Operating expenses: | Loss from operations | -26,229 | -22,922 | -50,473 | -44,737 |
| Other income (expense): | Interest expense | -1,097 | -264 | -2,165 | -265 |
| Other income (expense): | Interest income | 4,526 | 1,132 | 7,427 | 2,677 |
| Other income (expense): | Other income (expense), net | -25 | -92 | -177 | -77 |
| Other income (expense): | Total other income (expense), net | 3,404 | 776 | 5,085 | 2,335 |
| Other income (expense): | Net loss before income taxes | -22,825 | -22,146 | -45,388 | -42,402 |
| Other income (expense): | Income tax expense (benefit) |  |  |  | -681 |
| Other income (expense): | Net loss | -22,825 | -22,146 | -45,388 | -41,721 |
| Other income (expense): | Other comprehensive income — unrealized loss on investments | -814 | -36 | -1,110 | -66 |
| Other income (expense): | Comprehensive loss | -23,639 | -22,182 | -46,498 | -41,787 |
| Other income (expense): | Net loss per share, basic and diluted | -0.12 | -0.27 | -0.29 | -0.53 |
| Other income (expense): | Weighted-average common shares outstanding, basic and diluted | 185,443,736 | 81,477,548 | 155,121,235 | 78,529,028 |

### Balance Sheet (December 31, — (In thousands, except share and per-share amounts))

| | June 30, – 2026 – (Unaudited) | December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 63,008 | 43,760 |
| Current assets: | Restricted cash | 42 | 42 |
| Current assets: | Total cash, cash equivalents and restricted cash | 63,050 | 43,802 |
| Current assets: | Short-term investments | 263,273 | 229,696 |
| Current assets: | Accounts and other receivables | 3,341 | 1,219 |
| Current assets: | Income tax and R&D incentive receivables |  | 518 |
| Current assets: | Prepaid expenses and other current assets | 5,151 | 2,957 |
| Current assets: | Total current assets | 334,815 | 278,192 |
| Current assets: | Long-term investments | 192,247 |  |
| Current assets: | Property and equipment, net | 60 | 312 |
| Current assets: | Other assets | 90 | 1,425 |
| Current assets: | Total assets | 527,212 | 279,929 |
| Current liabilities: | Accounts payable | 1,272 | 2,717 |
| Current liabilities: | Accrued expenses and other current liabilities | 11,229 | 12,280 |
| Current liabilities: | Total current liabilities | 12,501 | 14,997 |
| Current liabilities: | Term loan, noncurrent | 34,742 | 34,287 |
| Current liabilities: | Other noncurrent liabilities | 5,761 | 5,753 |
| Current liabilities: | Total liabilities | 53,004 | 55,037 |
| Stockholders’ equity: | Common stock, $0.0001 par value; 400,000,000 and 200,000,000 shares authorized; 194,474,154 and 110,882,735 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 19 | 11 |
| Stockholders’ equity: | Additional paid-in capital | 1,175,098 | 879,292 |
| Stockholders’ equity: | Accumulated deficit | -694,871 | -649,483 |
| Stockholders’ equity: | Accumulated other comprehensive loss, net | -6,038 | -4,928 |
| Stockholders’ equity: | Total stockholders’ equity | 474,208 | 224,892 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 527,212 | 279,929 |
